DCV Technologies dcvtech.net


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

DCV Technologies, Inc. (DCV) is a private, biopharmaceutical company focusing on the development of therapeutic vaccines for reproductive tract and other cancers.

DCV Technologies, Inc. (DCV) is a private, biopharmaceutical company focusing on the development of therapeutic vaccines for reproductive tract and other cancers.

Company (Alive / Active)

Phone:

Fax:

Little Rock, 72205
Arkansas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
DCV Technologies $0M Nov 30, 2018
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related DCV Technologies Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Innoviva

Brisbane, California, United States
IPO / Went publicInnoviva, formerly known as Theravance, is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible...Show allLogin to see details

Immunovaccine

Dartmouth, Nova Scotia, Canada
IPO / Went publicIMV develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.Login to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)